MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Mesothelin targeted cancer immunotherapy

European Journal of Cancer. 2007 Oct 16; [Epub ahead of print] [Link]

Hassan R, Ho M.

Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264, USA.

Abstract

Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. Three mesothelin targeted agents are in various stages of clinical evaluation in patients. These include SS1P (CAT-5001) a recombinant immunotoxin targeting mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelin. These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.

Keywords: Mesothelioma; Ovarian cancer; Pancreatic cancer; Lung cancer; Tumour vaccine; Monoclonal antibodies; Clinical trial; CA-125; SS1P; MORAb-009

Both comments and trackbacks are currently closed.